BioCryst Pharmaceuticals（BCRX）株式概要
バイオテクノロジー企業であるバイオクリスト・ファーマシューティカルズ社は、遺伝性血管性浮腫（HAE）やその他の希少疾患の治療薬の開発・商業化を進めている。 詳細
BCRX Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
BioCryst Pharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$9.84 |
| 52週高値 | US$10.94 |
| 52週安値 | US$6.00 |
| ベータ | 0.54 |
| 1ヶ月の変化 | 17.00% |
| 3ヶ月変化 | 3.91% |
| 1年変化 | 10.07% |
| 3年間の変化 | 40.97% |
| 5年間の変化 | -39.85% |
| IPOからの変化 | 51.38% |
最新ニュース
ナラティブの更新 • Jun 17
BCRX: Rare Disease Pipeline Progress And Licensing Deal Will Drive Shares
BioCryst Pharmaceuticals saw its consensus analyst price target raised by a few dollars into the mid $30s, as analysts pointed to updated assumptions around revenue growth, profit margins, and future P/E multiples to support their revised valuation work. Analyst Commentary Bullish analysts covering BioCryst Pharmaceuticals have recently adjusted their models and raised price targets, reflecting updated views on revenue growth assumptions, profit margins, and the P/E multiples they are willing to apply to the stock.分析記事 • Jun 16
BioCryst (BCRX) Stock After New HAE Data Presentation Is The Undervaluation Story Still Intact
BioCryst Pharmaceuticals (BCRX) drew investor attention after presenting new clinical and real world data on its hereditary angioedema therapies ORLADEYO and navenibart at the European Academy of Allergy and Clinical Immunology meeting in Istanbul. See our latest analysis for BioCryst Pharmaceuticals. At a share price of US$9.06, BioCryst has seen short term momentum pick up around the EAACI data, with a 1 day share price return of 4.14% and year to date share price return of 20.80%. However,...Seeking Alpha • Jun 15
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
Summary BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelling pipeline with Orladeyo and navenibart. BCRX targets $1.8bn in revenues and $1bn in cash by 2033, leveraging best-in-class efficacy and less frequent dosing for navenibart to challenge market incumbents. Recent Q1 results showed 11% YoY Orladeyo revenue growth, robust non-GAAP profitability, and reaffirmed 2026 guidance, suggesting valuation remains attractive. Key risks for BCRX stock include intensifying competition, patent expiries post-2030, and potential clinical or manufacturing setbacks, but current momentum supports a 30–50% upside. Read the full article on Seeking AlphaRecent updates
ナラティブの更新 • Jun 17
BCRX: Rare Disease Pipeline Progress And Licensing Deal Will Drive Shares
BioCryst Pharmaceuticals saw its consensus analyst price target raised by a few dollars into the mid $30s, as analysts pointed to updated assumptions around revenue growth, profit margins, and future P/E multiples to support their revised valuation work. Analyst Commentary Bullish analysts covering BioCryst Pharmaceuticals have recently adjusted their models and raised price targets, reflecting updated views on revenue growth assumptions, profit margins, and the P/E multiples they are willing to apply to the stock.分析記事 • Jun 16
BioCryst (BCRX) Stock After New HAE Data Presentation Is The Undervaluation Story Still Intact
BioCryst Pharmaceuticals (BCRX) drew investor attention after presenting new clinical and real world data on its hereditary angioedema therapies ORLADEYO and navenibart at the European Academy of Allergy and Clinical Immunology meeting in Istanbul. See our latest analysis for BioCryst Pharmaceuticals. At a share price of US$9.06, BioCryst has seen short term momentum pick up around the EAACI data, with a 1 day share price return of 4.14% and year to date share price return of 20.80%. However,...Seeking Alpha • Jun 15
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
Summary BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelling pipeline with Orladeyo and navenibart. BCRX targets $1.8bn in revenues and $1bn in cash by 2033, leveraging best-in-class efficacy and less frequent dosing for navenibart to challenge market incumbents. Recent Q1 results showed 11% YoY Orladeyo revenue growth, robust non-GAAP profitability, and reaffirmed 2026 guidance, suggesting valuation remains attractive. Key risks for BCRX stock include intensifying competition, patent expiries post-2030, and potential clinical or manufacturing setbacks, but current momentum supports a 30–50% upside. Read the full article on Seeking Alpha
ナラティブの更新 • Jun 02
BCRX: HAE Portfolio Progress And European Deal Will Support Upside
Analysts have nudged their price targets on BioCryst Pharmaceuticals higher, with recent Street research pointing to a combined $4 increase as they update assumptions on revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts point to updates in revenue assumptions as a key driver behind the combined US$4 increase in price targets, suggesting more confidence in the company’s ability to translate its pipeline and products into higher sales over time.ナラティブの更新 • May 16
BCRX: Astria Integration And Licensing Deal Will Support Hereditary Angioedema Expansion
Analysts have nudged their average price target on BioCryst higher by low single digits in recent weeks, citing reiterated long-term revenue goals following the Astria Therapeutics acquisition, ongoing confidence in Orladeyo and navenibart sales potential, and steadier expectations for future profitability and P/E levels. Analyst Commentary Recent research has leaned constructive on BioCryst, with several bullish analysts adjusting their price targets upward and reaffirming confidence in the company’s long term revenue framework following the Astria Therapeutics acquisition.ナラティブの更新 • May 01
BCRX: Astria Deal And FY26 Goals Will Support Rare Disease Upside
Analysts have inched their average price target on BioCryst Pharmaceuticals higher by $0.10 to $21.40, reflecting research that points to steady commercial execution, reiterated long term revenue goals following the Astria Therapeutics acquisition, and continued interest in the BCX17725 program as well as Orladeyo and navenibart sales potential. Analyst Commentary Recent research highlights a mix of enthusiasm and caution around BioCryst, with price targets edging higher and coverage resuming as analysts digest the Astria Therapeutics acquisition, updated guidance, and the company’s rare disease portfolio.ナラティブの更新 • Apr 17
BCRX: Astria Integration And 2031 Debt Structure Will Support Hereditary Angioedema Expansion
Narrative Update Analysts have nudged their price targets on BioCryst Pharmaceuticals higher by $1. This reflects continued confidence in management's reiterated FY26 guidance, the integration of the Astria Therapeutics acquisition, and the longer term potential they see in Orladeyo and navenibart.ナラティブの更新 • Apr 03
BCRX: Astria Acquisition And FY26 Guidance Will Support Long-Term Revenue Potential
Analysts lifted their price target on BioCryst Pharmaceuticals to $22 from $21, citing steady forward guidance, reaffirmed peak revenue goals following the Astria Therapeutics acquisition, and confidence in Orladeyo and the BCX17725 program as key factors supporting the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as supported by reiterated FY26 guidance and peak revenue goals, which they view as evidence that management is confident in the current growth plan.
ナラティブの更新 • Mar 20
BCRX: Astria Acquisition And FY26 Outlook Will Support Long Term Upside
Analysts lifted their price targets on BioCryst to a range of $17 to $22, citing steady FY26 guidance, reaffirmed peak revenue goals, and confidence in the Astria Therapeutics acquisition and BCX17725 data timeline as key supports for the higher valuations. Analyst Commentary Recent Street research on BioCryst highlights a mix of optimism around the Astria Therapeutics acquisition, reaffirmed FY26 guidance, and the commercial trajectory of Orladeyo, alongside growing interest in the BCX17725 program as a potential long term driver.ナラティブの更新 • Mar 05
BCRX: Astria Acquisition And FY26 Outlook Will Support Long-Term HAE Leadership
Analysts have raised their blended price target on BioCryst Pharmaceuticals to about $21.30 from $20.50, citing reaffirmed FY26 guidance, reiterated peak revenue goals after the Astria Therapeutics acquisition, and continued confidence in the commercial ramp and the BCX17725 data timeline. Analyst Commentary Bullish Takeaways Bullish analysts see the higher blended price targets, up to about $22, as reflecting confidence in execution on the FY26 guidance and the longer term revenue framework.ナラティブの更新 • Feb 19
BCRX: Astria Acquisition Will Drive Hereditary Angioedema Franchise Expansion
Analysts have reaffirmed their $32.00 fair value estimate for BioCryst Pharmaceuticals and supported a $17.00 price target, citing expectations for Orladeyo to potentially reach $900m in sales by 2029 and for navenibart to approach $1b in risk adjusted sales following the Astria Therapeutics acquisition. Analyst Commentary Bullish analysts view the reaffirmed US$32.00 fair value estimate and the US$17.00 price target as grounded in a clearer revenue roadmap, with both Orladeyo and navenibart framed as key building blocks of the story rather than optional upside.ナラティブの更新 • Feb 05
BCRX: Pediatric Approval And 2031 Financing Will Strengthen Long Term Outlook
Narrative Update Overview Analysts have raised their price target on BioCryst Pharmaceuticals from US$11.00 to US$13.00, reflecting updated assumptions on revenue, profit margins, discount rate and future P/E multiples in their valuation work. What's in the News Entered a new loan agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. for term loans with gross proceeds of US$400 million, issued in multiple tranches and maturing on January 23, 2031, with quarterly interest-only payments and principal due at maturity (company announcement).ナラティブの更新 • Jan 22
BCRX: Pediatric Expansion And 2025 Profitability Outlook Will Support Long-Term HAE Leadership
Narrative Update Overview Analysts now see fair value for BioCryst Pharmaceuticals at US$20.50 per share, a US$0.10 adjustment that reflects updated assumptions on revenue growth, profit margins, discount rate, and future P/E levels. What's in the News BioCryst issued full year 2026 earnings guidance, with total revenue expected in a range of US$635 million to US$660 million (company guidance).ナラティブの更新 • Jan 08
BCRX: Astria Acquisition Will Extend HAE Leadership With Long Acting Injectable Through 2042
Narrative Update: BioCryst Pharmaceuticals The updated analyst price target for BioCryst Pharmaceuticals has moved modestly higher to about $20.60 from $20.40, with analysts pointing to the planned $700m acquisition of Astria Therapeutics, expected SG&A synergies, and the potential of HAE candidate navenibart to support BioCryst's hereditary angioedema franchise as key reasons for their revised view. Analyst Commentary Street research around BioCryst's planned US$700m acquisition of Astria Therapeutics clusters around the same core themes, but with different levels of enthusiasm about execution risk, competitive pressure, and valuation.ナラティブの更新 • Dec 24
BCRX: Astria Acquisition Will Extend Hereditary Angioedema Leadership Through Navenibart
We raise our BioCryst Pharmaceuticals fair value estimate to $32.00 from $28.15, as analysts highlight the accretive $700M Astria Therapeutics acquisition and its potential to extend the company’s hereditary angioedema leadership with long acting navenibart through the next decade. Analyst Commentary Analysts with a positive view on the stock are broadly endorsing BioCryst's acquisition of Astria Therapeutics, describing it as a value-accretive move that enhances the company’s hereditary angioedema portfolio and extends its potential growth runway into the 2030s and beyond.ナラティブの更新 • Dec 10
BCRX: Astria Acquisition Will Extend HAE Leadership With Long-Acting Injectable Through 2042
Analysts have lifted their average price targets on BioCryst Pharmaceuticals by a mid-teens dollar amount into the mid to high $20s per share range, citing the proposed $700M acquisition of Astria Therapeutics as a strategically sound, earnings-accretive move that extends the company’s hereditary angioedema leadership and reduces long-term growth risk. Analyst Commentary Street research following the Astria Therapeutics deal skews constructive, with most price target revisions reflecting higher confidence in BioCryst’s long term growth profile and durability in hereditary angioedema, even as investors weigh near term dilution and competitive risks.ナラティブの更新 • Nov 26
BCRX: Acquisition Will Extend HAE Franchise With New Long-Acting Candidate Through 2042
BioCryst Pharmaceuticals’ fair value estimate has increased from $19.73 to $20.40 per share. Analysts cite the company’s acquisition of Astria Therapeutics and improved long-term growth prospects following recent price target raises by multiple firms.ナラティブの更新 • Nov 12
BCRX: Acquisition Will Drive Earnings Upside With New HAE Candidate Through 2042
BioCryst Pharmaceuticals' fair value estimate has been adjusted downward by approximately $0.55 per share, as analysts incorporate the strategic rationale and expected synergies following the announced acquisition of Astria Therapeutics. Analyst Commentary Market observers have provided a range of insights following BioCryst Pharmaceuticals' acquisition of Astria Therapeutics.分析記事 • Nov 06
Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Last week saw the newest third-quarter earnings release from BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ), an...ナラティブの更新 • Oct 29
Acquisition Of Leading HAE Therapy Candidate Will Drive Future Market Expansion
Analysts have raised their price target for BioCryst Pharmaceuticals from $18.50 to approximately $20.27 per share. This change reflects optimism about the company's acquisition of Astria Therapeutics and its anticipated impact on future growth and market position.ナラティブの更新 • Oct 14
Expanding Rare Disease Pipeline Will Open New Markets
Analysts have raised their fair value estimate for BioCryst Pharmaceuticals to $18.50 from $16.73. They cited the anticipated long-term benefits and strategic alignment from the recent Astria Therapeutics acquisition, despite some near-term uncertainties.分析記事 • Aug 07
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
A week ago, BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) came out with a strong set of quarterly numbers that could...新しいナラティブ • May 09
ORLADEYO Pipeline Will Deliver New Therapeutic Opportunities
ORLADEYO's revenue growth, patient conversion, and reduced royalty payments enhance profitability, cash flow, and financial stability for BioCryst Pharmaceuticals.Seeking Alpha • Feb 25
BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical
Summary I initially rated BioCryst a "Sell" in November 2023, but am now upgrading to "Hold" as the company has outperformed my expectations, despite competitive pressures. Orladeyo, BioCryst's main revenue source, saw impressive growth in 2024, but faces significant competition and may not reach management's $1bn annual revenue target in my view. Q4 2024 earnings showed a notable improvement with a reduced GAAP operating loss and a positive non-GAAP operating profit, but guidance for ~22% growth led to a sell-off. Despite promising near-term growth and potential label expansions, long-term risks and reliance on Orladeyo remain concerns, making the stock fairly valued at this time in my view. Read the full article on Seeking Alpha分析記事 • Feb 15
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Fly 25% But Investors Aren't Buying For Growth
The BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) share price has done very well over the last month, posting an...株主還元
| BCRX | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -1.0% | 4.1% | 1.6% |
| 1Y | 10.1% | 41.1% | 18.6% |
業界別リターン: BCRX過去 1 年間で41.1 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: BCRXは、過去 1 年間で18.6 % のリターンを上げたUS市場を下回りました。
価格変動
| BCRX volatility | |
|---|---|
| BCRX Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: BCRX 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: BCRXの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1986 | 435 | Charlie Gayer | www.biocryst.com |
バイオクリスト・ファーマシューティカルズ社（BioCryst Pharmaceuticals, Inc.）は、遺伝性血管性浮腫（HAE）およびその他の希少疾患の治療薬の開発・販売を行うバイオテクノロジー企業である。 同社は、急性非合併症型および季節性インフルエンザの治療薬である静脈内投与用ノイラミニダーゼ阻害剤「ペラミビル注射液」を、「RAPIVAB」、「RAPIACTA」、「PERAMIFLU」の商品名で販売しているほか、HAEの治療薬である経口セリンプロテアーゼ阻害剤「ORLADEYO」も販売している。 また、ネザートン症候群治療用のタンパク質治療薬「BCX17725」（第1相臨床試験中）、糖尿病性黄斑浮腫治療用の眼用血漿カリクレイン阻害剤「アボラルスタット」（第1相臨床試験中）、 HAE治療用のモノクローナル抗体型血漿カリクレイン阻害剤「Navenibart」（第3相試験中）；ネザートン症候群治療用のKLK5阻害剤であるタンパク質治療薬「BCX17725」（第1相臨床試験中）； STAR-0310：アトピー性皮膚炎の治療を目的としたモノクローナル抗体OX40拮抗薬で、第1a相試験段階にある。同社は、鳥居薬品株式会社、塩野義製薬株式会社、グリーンクロス株式会社と提携およびライセンス導入関係を結んでいる； 米国国立アレルギー・感染症研究所（NIAID）、生物医学先端研究開発局（BARDA）、米国保健社会福祉省（HHS）、イェシーバ大学アルバート・アインシュタイン医科大学、およびインダストリアル・リサーチ社。バイオクリスト・ファーマシューティカルズ社は1986年に設立され、本社はノースカロライナ州ダーラムにある。
BioCryst Pharmaceuticals, Inc. 基礎のまとめ
| BCRX 基礎統計学 | |
|---|---|
| 時価総額 | US$2.50b |
| 収益（TTM） | -US$457.98m |
| 売上高(TTM) | US$885.72m |
2.8x
P/Sレシオ-5.5x
PER（株価収益率BCRX は割高か？
公正価値と評価分析を参照収益と収入
| BCRX 損益計算書（TTM） | |
|---|---|
| 収益 | US$885.72m |
| 売上原価 | US$207.02m |
| 売上総利益 | US$678.70m |
| その他の費用 | US$1.14b |
| 収益 | -US$457.98m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.80 |
| グロス・マージン | 76.63% |
| 純利益率 | -51.71% |
| 有利子負債／自己資本比率 | -152.2% |
BCRX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/05 22:52 |
| 終値 | 2026/07/02 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
BioCryst Pharmaceuticals, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27
| アナリスト | 機関 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |